Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome.
Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome.
Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
Location: United States
Employees: 51-200
Phone: +1 650-667-4085
Total raised: $120M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Frazier Li... | frazierls.... |
| 25.10.2023 | Longitude ... | longitudec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.11.2018 | Series A | $120M | New Enterp... |
Mentions in press and media 18
| Date | Title | Description |
| 31.01.2026 | Concourse Unlocks Finance Efficiency with $12M Series A, Broad AI Agent Launch | Concourse secured $12M in Series A funding. Standard Capital led the investment round. The AI agent platform for finance teams is now generally available. It automates critical financial operations. The platform integrates with existing sys... |
| 27.01.2026 | Concourse Raises $12M in Series A Funding | Concourse, a NYC-based provider of an AI agent platform for finance teams, raised $12M Series A funding. The round led by Standard Capital, with participation from Andreessen Horowitz, CRV, and Y Combinator, as well as CFO angels from compa... |
| 27.01.2026 | Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics | Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a Foster City, Calif.-based rare disease company, completed its acquisition of Bluejay Therapeutics, a Redwood City, CA-based biotechnology company focused on viral and liver diseases. Under the t... |
| 09.12.2025 | Mirum Pharmaceuticals to Acquire Bluejay Therapeutics, for Up To $820M | Mirum Pharmaceuticals (Nasdaq: MIRM), a Foster, City, CA-based rare disease company, is to acquire Bluejay Therapeutics, a San Francisco, CA-based biotechnology company focused on viral and liver diseases, for up to $820m. Under the terms o... |
| 01.08.2025 | Frazier Life Sciences: $1.3 Billion Venture Fund Closed | Frazier Life Sciences (FLS), an investment firm focused on innovative therapeutics, announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong s... |
| 06.02.2025 | Genomenon and Mirum Pharmaceuticals Join Forces to Enhance CTX Disease Awareness and Diagnosis | Genomenon logo Data on CYP27A1 Variants Available to Genetic Testing Labs Around the World ANN ARBOR, Mich., Feb. 6, 2025 /PRNewswire-PRWeb/ -- Genomenon, Inc., a leading provider of genomic intelligence solutions, has announced a strategic... |
| 13.04.2021 | Vivet Therapeutics, participada por Ysios Capital y Columbus Venture, cierra una opción exclusiva de licencia con Mirum Pharmaceuticals | 13/04/2021 Nota de prensa MIRUM PHARMACEUTICALS Y VIVET THERAPEUTICS FIRMAN UN ACUERDO EXCLUSIVO DE OPCIÓN Y LICENCIA A ESCALA MUNDIAL PARA LOS PROGRAMAS DE TERAPIA GÉNICA DE VIVET DIRIGIDOS A LA COLESTASIS INTRAHEPÁTICA FAMILIAR PROGRESI... |
| 13.04.2021 | Vivet Therapeutics, participated by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals | 13/04/2021 Press release MIRUM PHARMACEUTICALS AND VIVET THERAPEUTICS ENTER INTO EXCLUSIVE WORLDWIDE OPTION AND LICENSE AGREEMENT FOR VIVET’S GENE THERAPY PROGRAMS TARGETING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS. – Mirum expands ... |
| 10.03.2021 | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2021, the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to pu... |
| 30.12.2020 | Mirum Pharmaceuticals, Inc. announced that it has received $10 million in funding from Oberland Capital Management LLC and other investors | On December 30, 2020, Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) closed the transaction. The company raised $10,000,000 pursuant to Regulation D from 3 investors. |
Show more